-
Lioresal:
GENERIC
INDICATION
DOSE
MOA
ADR
DDI
- 1. Baclofen
- 2. SPASTICITY, management of reversible spasticity associated w/ MS; spinal cord injury
- 3. inhibits transmission of both monosynaptic and polysynaptic reflexes at the spinal cord level, possibly by hyperpolarizationof the fiber terminals resulting in muscle spasticity relief.
- 4. Black Box: Avoid abrupt withdrawal (injection); rebound spasticity, altered mental status, hyperpyrexia, rare rhabdo, organsystem failure, death.
- 5. Avoid alcohol, benzos, analgesics, and other CNS depressants when possible
-
Zanaflex:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. tizanidine
- 2. alpha2-adrenergic agonist
- 3. Spasticity
- 4. 2mg up to Q6-8H prn
- 5. alpha2-adrenergic agonist agent which decreases spasticity by increasing presynaptic inhibition; effects are greatest on polysynaptic pathways; overall effect is to reduce facilitation of spinal motor neurons.
- 6. Hepatotoxicity, hypotension, sedation, visual hallucinations, hypersensitivity, renal impairment; pregnancy C category
- 7. Ciprofloxacin and fluvoxamine (potent CYP1a2 inhibitors); CNS depressants (benzos, opioids)
-
Nuedexta:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. dextromethorphan/quinidine
- 2. NMDA receptor antagonist
- 3. Pseudobulbar affect (PBA) - uncontrollable outbursts of crying or laughing
- 4. 20 mg PO QD 7x days, then Q12H
- 5.Dextromethorphan may relieve the symptoms of PBA by binding to sigma-1
- receptors in the brain which may be involved in behavior, however the exact mechanism of action is not known. Quinidine is used to block the rapid metabolism of dextromethorphan, thereby increasing serum concentrations.
- 6.
- 7. Amiodarone (enhance QTc w/ quinidine)
-
Ampyra:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. dalfampridine
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
-
Avonex/Rebif:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. interferon beta-1a
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
-
Betaseron/Extavia:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. interferon beta-1b
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
-
Copaxone:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. glatiramer acetate
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
-
Lemtrada:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. alemtuzumab
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
-
Tysabri:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. natalizumab
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
-
Novantrone:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. mitoxantrone
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
-
Gilenya:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. fingolimod
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
-
Aubagio:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. teriflunomide
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
-
Tecfidera:
GENERIC
CLASS
INDICATION
DOSE
MOA
ADR
DDI
- 1. dimethyl fumerate
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
|
|
